{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:57:45Z","timestamp":1792735065878,"version":"4.5.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40265-023-01942-0","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T10:03:03Z","timestamp":1695117783000},"page":"1351-1363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Escalation Versus Induction\/High-Efficacy Treatment Strategies for Relapsing Multiple Sclerosis: Which is Best for Patients?"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9641-6734","authenticated-orcid":false,"given":"Gilles","family":"Edan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Le Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"issue":"2","key":"1942_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96\u2013120.","journal-title":"Mult Scler"},{"issue":"17","key":"1942_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","volume":"90","author":"A Rae-Grant","year":"2018","unstructured":"Rae-Grant A, Day G, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777\u201388.","journal-title":"Neurology"},{"key":"1942_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209\u201320.","journal-title":"N Engl J Med"},{"key":"1942_CR4","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263\u201373.","journal-title":"Lancet"},{"issue":"5","key":"1942_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1474-4422(18)30108-X","volume":"17","author":"G Edan","year":"2018","unstructured":"Edan G. Natalizumab in secondary progressive multiple sclerosis. Lancet Neurol. 2018;17(5):384\u20135. https:\/\/doi.org\/10.1016\/S1474-4422(18)30108-X. (Epub 2018 Mar 12).","journal-title":"Lancet Neurol"},{"key":"1942_CR6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","volume":"63","author":"H Panitch","year":"2004","unstructured":"Panitch H, Miller A, Paty D, et al. North American Study Group on interferon beta 1b in secondary progressive MS: results from a 3 year controlled study. Neurology. 2004;63:1788\u201395.","journal-title":"Neurology"},{"key":"1942_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s00415-005-0934-5","volume":"253","author":"AJ Coles","year":"2006","unstructured":"Coles AJ, Cox E, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253:98\u2013108.","journal-title":"J Neurol"},{"key":"1942_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","volume":"66","author":"K Hawker","year":"2009","unstructured":"Hawker K, O\u2019Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460\u201371.","journal-title":"Ann Neurol"},{"key":"1942_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(15)01314-8","volume":"387","author":"F Lublin","year":"2016","unstructured":"Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387:1075\u201384.","journal-title":"Lancet"},{"key":"1942_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","volume":"17","author":"R Kapoor","year":"2018","unstructured":"Kapoor R, Ho P-R, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo controlled trial with an open-label extension. Lancet Neurol. 2018;17:405\u201315.","journal-title":"Lancet Neurol"},{"key":"1942_CR11","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awq076","volume":"133","author":"E Leray","year":"2010","unstructured":"Leray E, Yaouanq J, Le Page E, et al. Evidence of a two stage disability progression in multiple sclerosis. Brain. 2010;133:1900\u201313.","journal-title":"Brain"},{"key":"1942_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","volume":"343","author":"C Confavreux","year":"2000","unstructured":"Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430\u20138.","journal-title":"N Engl J Med"},{"key":"1942_CR13","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awq118","volume":"133","author":"A Scalfari","year":"2010","unstructured":"Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study. 10. Relapses and long-term disability. Brain. 2010;133:1914\u201329.","journal-title":"Brain"},{"key":"1942_CR14","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1212\/WNL.0b013e3181e3973f","volume":"74","author":"H Tremlett","year":"2010","unstructured":"Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74:2004\u201315.","journal-title":"Neurology"},{"key":"1942_CR15","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/brain\/awv105","volume":"138","author":"M Tintore","year":"2015","unstructured":"Tintore M, Rovira A, Rio J, et al. Developing high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015;138:1863\u201374.","journal-title":"Brain"},{"key":"1942_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ana.21640","volume":"65","author":"HL Weiner","year":"2009","unstructured":"Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol. 2009;65:239\u201348.","journal-title":"Ann Neurol"},{"key":"1942_CR17","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/brain\/awr128","volume":"134","author":"L Haider","year":"2011","unstructured":"Haider L, Fisher MT, Frisher JM, et al. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134:1914\u201324.","journal-title":"Brain"},{"key":"1942_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, et al. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577.","journal-title":"Front Neurol"},{"key":"1942_CR19","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1007\/s10072-008-0954-x","volume":"29","author":"G Comi","year":"2008","unstructured":"Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci. 2008;29:S253\u20135.","journal-title":"Neurol Sci"},{"issue":"6","key":"1942_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neurol.2018.04.004","volume":"174","author":"E Le Page","year":"2018","unstructured":"Le Page E, Edan G. Induction or escalation therapy for patients with multiple sclerosis? Rev Neurol (Paris). 2018;174(6):449\u201357. https:\/\/doi.org\/10.1016\/j.neurol.2018.04.004.","journal-title":"Rev Neurol (Paris)"},{"key":"1942_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/jpm12010119","volume":"12","author":"B Casanova","year":"2022","unstructured":"Casanova B, Quintanilla-Bord\u00e0s C, Gascon F. Escalation vs. early intense therapy in multiple sclerosis. J Pers Med. 2022;12:119. https:\/\/doi.org\/10.3390\/jpm12010119.","journal-title":"J Pers Med"},{"key":"1942_CR22","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1007\/s00415-021-10836-8","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Danes R, Derfus T, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269:1670\u20137.","journal-title":"J Neurol"},{"key":"1942_CR23","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1212\/WNL.0000000000002830","volume":"87","author":"MP Sormani","year":"2016","unstructured":"Sormani MP, Gasperini C, Romeo M, et al. Assessing response to interferon-b in a multicenter dataset of patients with MS. Neurology. 2016;87:134\u201340.","journal-title":"Neurology"},{"key":"1942_CR24","unstructured":"Ruggieri S, Prosperini L, Al-Araji S, et al. Assessing treatment response to oral drugs for multiple sclerosis in real world setting: a MAGNIMS study. Poster communication. ECTRIMS Congress, Amsterdam, 27 October 2022; 2022."},{"issue":"24","key":"1942_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1212\/WNL.0000000000005574","volume":"90","author":"JR Corboy","year":"2018","unstructured":"Corboy JR, Weinshenker BG, Wingerchuk DW. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. Neurology. 2018;90(24):1106\u201312.","journal-title":"Neurology"},{"key":"1942_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00415-009-0093-1","volume":"256","author":"M Hutchinson","year":"2009","unstructured":"Hutchinson M, Kappos L, Calabresi P, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405\u201315.","journal-title":"J Neurol"},{"key":"1942_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intra-muscular interferon beta for relapsing multiple sclerosis. N Engl J Med. 2010;362:402\u201315.","journal-title":"N Engl J Med"},{"key":"1942_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Ba-Or A, Comi G, et al. Ocrelizumab versus interferon beta 1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"issue":"9856","key":"1942_CR29","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon-beta-1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819\u201328.","journal-title":"Lancet"},{"issue":"9856","key":"1942_CR30","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised phase 3 trial. Lancet. 2012;380(9856):1829\u201339.","journal-title":"Lancet"},{"key":"1942_CR31","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/jnnp.2010.229724","volume":"82","author":"G Edan","year":"2011","unstructured":"Edan G, Comi G, Le Page E, et al. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82:1344\u201350.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1942_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2018.20588","volume":"321","author":"JWL Brown","year":"2019","unstructured":"Brown JWL, Coles A, Horakova D, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA. 2019;321(2):175\u201387.","journal-title":"JAMA"},{"issue":"8","key":"1942_CR33","doi-asserted-by":"publisher","first-page":"e1041","DOI":"10.1212\/WNL.0000000000010135","volume":"95","author":"MD Buron","year":"2020","unstructured":"Buron MD, Chalmer TA, Sellebjerg F, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95(8):e1041\u201351.","journal-title":"Neurology"},{"key":"1942_CR34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","volume":"76","author":"K Harding","year":"2019","unstructured":"Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536\u201341.","journal-title":"JAMA Neurol"},{"key":"1942_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown W, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307\u201316.","journal-title":"Lancet Neurol"},{"key":"1942_CR36","doi-asserted-by":"publisher","first-page":"175628642110195","DOI":"10.1177\/17562864211019574","volume":"14","author":"P Iaffaldano","year":"2021","unstructured":"Iaffaldano P, Lucisano G, Caputo F, et al. Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies. Ther Adv Neurol Disord. 2021;14:17562864211019574.","journal-title":"Ther Adv Neurol Disord"},{"key":"1942_CR37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s13311-020-00847-0","volume":"17","author":"L Prosperini","year":"2020","unstructured":"Prosperini L, Mancinelli CR, Solaro CM, et al. Induction versus escalation in multiple sclerosis: a 10-year real world study. Neurotherapeutics. 2020;17:994\u20131004.","journal-title":"Neurotherapeutics"},{"issue":"10","key":"1942_CR38","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman T, Magyari M, Piehl F, et al. Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol. 2021;78(10):1197\u2013204.","journal-title":"JAMA Neurol"},{"key":"1942_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104803","author":"T Hrnciarova","year":"2023","unstructured":"Hrnciarova T, Drhota J, Spelman T, et al. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries. Mult Scler Relat Disord. 2023. https:\/\/doi.org\/10.1016\/j.msard.2023.104803.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"1942_CR40","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"C Polman","year":"2006","unstructured":"Polman C, O\u2019Connor PW, Havrdora E, et al. A randomized, placebo controlled trial of natalizumab of relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"key":"1942_CR41","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","volume":"91","author":"H Butzkueven","year":"2020","unstructured":"Butzkueven H, Kappos L, Wiendl H, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry. 2020;91:660\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"1942_CR42","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","volume":"16","author":"PR Ho","year":"2017","unstructured":"Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal encephalopathy with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925\u201393.","journal-title":"Lancet Neurol"},{"issue":"1\u20132","key":"1942_CR43","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jns.2011.05.043","volume":"308","author":"A Kerbrat","year":"2011","unstructured":"Kerbrat A, Le Page E, Leray E, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing-remitting multiple sclerosis patients. J Neurol Sci. 2011;308(1\u20132):98\u2013102.","journal-title":"J Neurol Sci"},{"issue":"17","key":"1942_CR44","doi-asserted-by":"publisher","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","volume":"99","author":"I Roos","year":"2022","unstructured":"Roos I, Malpas C, Leray E, et al. Disease reactivation after cessation of disease modifying therapy in patients with relapsing remitting multiple sclerosis. Neurology. 2022;99(17):e1926\u201344.","journal-title":"Neurology"},{"key":"1942_CR45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10072-014-1960-9","volume":"36","author":"L Ferre","year":"2015","unstructured":"Ferre L, Moiola L, Sangalli F, et al. Recurrence of disease activity after repeated natalizumab withdrawals. Neurol Sci. 2015;36:465\u20137.","journal-title":"Neurol Sci"},{"issue":"6","key":"1942_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled phase 3 trial. Lancet Neurol. 2014;13(6):545\u201356.","journal-title":"Lancet Neurol"},{"key":"1942_CR47","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419878324","author":"JA Cohen","year":"2019","unstructured":"Cohen JA, Tenenbaum N, Bhatt A, et al. Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019. https:\/\/doi.org\/10.1177\/1756286419878324.","journal-title":"Ther Adv Neurol Disord"},{"issue":"7","key":"1942_CR48","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","volume":"73","author":"SE Hatcher","year":"2016","unstructured":"Hatcher SE, Waubant E, Noubakhsh B, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol. 2016;73(7):790\u20134.","journal-title":"JAMA Neurol"},{"issue":"10127","key":"1942_CR49","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263\u201373.","journal-title":"Lancet"},{"issue":"5","key":"1942_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2021.0405","volume":"78","author":"L Kappos","year":"2021","unstructured":"Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study. JAMA Neurol. 2021;78(5):1\u201310.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1942_CR51","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1474-4422(19)30239-X","volume":"18","author":"G Comi","year":"2019","unstructured":"Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019;18(11):1009\u201320.","journal-title":"Lancet Neurol"},{"key":"1942_CR52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277","author":"SL Hauser","year":"2016","unstructured":"Hauser SL, Ba-or A, Comi G, et al. Ocrelizumab versus interferon beta 1a in relapsing multiple sclerosis. N Engl J Med. 2016. https:\/\/doi.org\/10.1056\/NEJMoa1601277.","journal-title":"N Engl J Med"},{"issue":"6","key":"1942_CR53","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA. ASCLEPIOS I and ASCLEPIOS II Trial Groups: ofatunumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357.","journal-title":"N Engl J Med"},{"key":"1942_CR54","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman L, Fox E, Hartung HP, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387:704\u201314.","journal-title":"N Engl J Med"},{"key":"1942_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000006916","volume":"92","author":"JM Honce","year":"2019","unstructured":"Honce JM, Nair KV, Sillau S, et al. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019;92:1\u201310.","journal-title":"Neurology"},{"key":"1942_CR56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11926-021-01037-3","volume":"23","author":"CD Varley","year":"2021","unstructured":"Varley CD, Winthrop KL. Long-term safety of rituximab (risks of viral and opportunist infections). Curr Rheumatol Rep. 2021;23:74.","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"1942_CR57","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.40937","volume":"71","author":"MYM Yusof","year":"2019","unstructured":"Yusof MYM, Vital EM, McElvenny DM, et al. Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2019;71(11):1812\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"1942_CR58","first-page":"1","volume":"14","author":"A Achiron","year":"2021","unstructured":"Achiron A, Mandel M, Dreyer-Alster S, et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord. 2021;14:1\u20138.","journal-title":"Ther Adv Neurol Disord"},{"key":"1942_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286419836913","volume":"12","author":"PS Sorensen","year":"2019","unstructured":"Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1\u201316.","journal-title":"Ther Adv Neurol Disord"},{"issue":"9350","key":"1942_CR60","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"P Hartung","year":"2002","unstructured":"Hartung P, Hartung HP, Gonsette R, et al. Mitoxantrone in prtogressive multiple sclerosis: a placebo-controlled double-blind, randomized, multicenter trial. Lancet. 2002;360(9350):2018\u201325.","journal-title":"Lancet"},{"key":"1942_CR61","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1136\/jnnp.62.2.112","volume":"62","author":"G Edan","year":"1997","unstructured":"Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicenter study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62:112\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1942_CR62","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1177\/1352458507085759","volume":"14","author":"T Vollmer","year":"2008","unstructured":"Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14:663\u201370.","journal-title":"Mult Scler"},{"issue":"6","key":"1942_CR63","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.neurol.2021.11.014","volume":"178","author":"M Lefort","year":"2022","unstructured":"Lefort M, Le Corre G, Le Page E, et al. Ten-year follow-up after mitoxantrone induction for early highly active relapsing-remitting multiple sclerosis: an observational study of 100 consecutive patients. Rev Neurol (Paris). 2022;178(6):569\u201379.","journal-title":"Rev Neurol (Paris)."},{"key":"1942_CR64","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/1352458511398371","volume":"17","author":"E Le Page","year":"2011","unstructured":"Le Page E, Leray E, Edan G, et al. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler. 2011;17:867\u201375.","journal-title":"Mult Scler"},{"issue":"2","key":"1942_CR65","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1756285611433318","volume":"5","author":"A Stroet","year":"2012","unstructured":"Stroet A, Hemmelmann C, Starck M, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord. 2012;5(2):75\u20139.","journal-title":"Ther Adv Neurol Disord"},{"issue":"21","key":"1942_CR66","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1212\/WNL.0b013e318238ee00","volume":"77","author":"V Martinelli","year":"2011","unstructured":"Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011;77(21):1887\u201395.","journal-title":"Neurology"},{"key":"1942_CR67","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"CAMMS223 Trial Investigators","year":"2008","unstructured":"CAMMS223 Trial Investigators. Alemtuzumab vs. interferon-beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786\u2013801.","journal-title":"N Engl J Med"},{"issue":"14","key":"1942_CR68","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0b013e31824e8ee7","volume":"78","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon b-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069\u201378.","journal-title":"Neurology"},{"issue":"11","key":"1942_CR69","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","volume":"89","author":"AJ Coles","year":"2017","unstructured":"Coles AJ, Cohen JA, Fox EJ, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89(11):1117\u201326.","journal-title":"Neurology"},{"key":"1942_CR70","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00749-x","author":"T Ziemssen","year":"2020","unstructured":"Ziemssen T, Bass AD, Berkovich R, et al. Efficacy and safety of alemtuzumab through 9 years of follow-up in patients with highly active disease: post hoc analysis of CARE-MS I and II patients in the TOPAZ extension study. CNS Drugs. 2020. https:\/\/doi.org\/10.1007\/s40263-020-00749-x.","journal-title":"CNS Drugs"},{"issue":"12","key":"1942_CR71","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1177\/1352458518796675","volume":"25","author":"S Wray","year":"2019","unstructured":"Wray S, Havrdova E, Snydman DR, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2019;25(12):1605\u201317.","journal-title":"Mult Scler"},{"key":"1942_CR72","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40265-020-01437-2","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Alemtuzumab: a review in relapsing remitting multiple sclerosis. Drugs. 2021;81:157\u201368.","journal-title":"Drugs"},{"key":"1942_CR73","unstructured":"European Medicines Agency. Lemtrada assessment report: procedure under article 20 of regulation (EC) No 726\/2004 resulting from pharmacovigilance data. 2019. https:\/\/www.ema.europa.eu\/. Accessed 10 Sept 2023."},{"key":"1942_CR74","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416\u201326.","journal-title":"N Engl J Med"},{"key":"1942_CR75","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Soelberg Sorensen P, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2017. https:\/\/doi.org\/10.1177\/1352458517727603.","journal-title":"Mult Scler"},{"key":"1942_CR76","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211049392","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Singer BA, Issard D, et al. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: the CLARITY extension study. Mult Scler. 2021. https:\/\/doi.org\/10.1177\/13524585211049392.","journal-title":"Mult Scler"},{"issue":"9","key":"1942_CR77","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1007\/s12325-021-01865-w","volume":"38","author":"G Giovannoni","year":"2021","unstructured":"Giovannoni G, Comi G, Rammohan K, et al. Long-term disease stability assessed by the Expanded Disability Status Scale in patients treated with cladribine tablets 3.5 mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY Extension studies. Adv Ther. 2021;38(9):4975\u201385.","journal-title":"Adv Ther"},{"key":"1942_CR78","doi-asserted-by":"publisher","first-page":"175628642092268","DOI":"10.1177\/1756286420922685","volume":"13","author":"F Patti","year":"2020","unstructured":"Patti F, Visconti A, Capacchione A, et al. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020;13:1756286420922685.","journal-title":"Ther Adv Neurol Disord"},{"key":"1942_CR79","unstructured":"EMC. Mavenclad 10 mg tablets summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/8435. Accessed 10 Sept 2023."},{"key":"1942_CR80","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-022-00339-7","volume":"11","author":"G Giovannoni","year":"2022","unstructured":"Giovannoni G, Mathews J. Cladribine. Tablets for relapsing-remitting multiple sclerosis: a clinician\u2019s review. Neurol Ther. 2022;11:571\u201395.","journal-title":"Neurol Ther"},{"key":"1942_CR81","doi-asserted-by":"crossref","unstructured":"Sharrack B, Saccardi R, Alexander T et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommandations from EBMT Autoimmune Diseases Working Party and the Joint Accreditation Committee of EBMT and ISCT. Bone Marrow Transplant. 2020;55(2):283-306.","DOI":"10.1038\/s41409-019-0684-0"},{"key":"1942_CR82","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","volume":"88","author":"MP Sormani","year":"2017","unstructured":"Sormani MP, Muraro PA, Schiaverri I, et al. Autologous hematopoietic stem cell transplantation: a meta analysis. Neurology. 2017;88:2115\u201322.","journal-title":"Neurology"},{"key":"1942_CR83","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011461","author":"G Boffa","year":"2021","unstructured":"Boffa G, Massacesi L, Inglese M, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology. 2021. https:\/\/doi.org\/10.1212\/WNL.0000000000011461.","journal-title":"Neurology"},{"issue":"11","key":"1942_CR84","doi-asserted-by":"publisher","first-page":"e1109","DOI":"10.1212\/WNL.0000000000206750","volume":"100","author":"G Boffa","year":"2023","unstructured":"Boffa G, Signori A, Massaceci L, et al. Hematopoietic stem cell transplantation in people with active secondary progressive secondary multiple sclerosis. Neurology. 2023;100(11):e1109\u201322.","journal-title":"Neurology"},{"issue":"8","key":"1942_CR85","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1136\/jnnp-2022-328797","volume":"93","author":"SA Strokke Kvistad","year":"2022","unstructured":"Strokke Kvistad SA, Burman J, Lehmann AK, et al. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. J Neurol Neurosurg Psychiatry. 2022;93(8):844\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"1942_CR86","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/jamaneurol.2020.4025","volume":"78","author":"AE Miller","year":"2021","unstructured":"Miller AE, Chitnis T, Cohen BA, et al. Autologous hematopoietic stem cell transplant in\u00a0multiple\u00a0sclerosis: recommendations of the National\u00a0Multiple\u00a0Sclerosis\u00a0Society. JAMA Neurol. 2021;78(2):241\u20136.","journal-title":"JAMA Neurol"},{"key":"1942_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104770","volume":"76","author":"G Seifer","year":"2023","unstructured":"Seifer G, Arun T, Capela C, et al. Influence of physicians\u2019 risk perception on switching treatments between high-efficacy and non-high-efficacy disease modifying therapies in multiple sclerosis. Mult Scler Relat Disord. 2023;76: 104770.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"1942_CR88","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neurad.2020.01.083","volume":"47","author":"JC Brisset","year":"2020","unstructured":"Brisset JC, Kremer S, Hannoun S, et al. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions. J Neuroradiol. 2020;47(4):250\u20138.","journal-title":"J Neuroradiol"},{"issue":"8","key":"1942_CR89","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20(8):653\u201370.","journal-title":"Lancet Neurol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01942-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T16:24:51Z","timestamp":1697559891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01942-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":89,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1942"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01942-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"6 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No specific funding was recieved for the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Both authors were involved as investigators in most of the phase 3 trials of approved DMDs and our institution received occasionally research grants from the industrials : Biogen, merck, Teva, Bayer, Novartis, Sanofi and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This manuscript has no associated data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Both authors contributed to this review.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}